Neuroendocrine (Small-cell) carcinomas: Why they teach us essential lessons about prostate cancer

ONCOLOGY (United States)

Volumn 28, Issue 10, 2014, Pages

  Aparicio, Ana ^a   Tzelepi, Vassiliki ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANDROGEN RECEPTOR; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CD56 ANTIGEN; CHROMOGRANIN; CHROMOGRANIN A; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; LEUPRORELIN; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR; VINCRISTINE;

ARTICLE; BONE LESION; BRAIN METASTASIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIGITAL RECTAL EXAMINATION; DISEASE COURSE; DISEASE MARKER; GENE EXPRESSION; GLEASON SCORE; HEMOSPERMIA; HORMONE RESISTANCE; HUMAN; IMAGING; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LYMPHADENOPATHY; LYMPHEDEMA; MULTIPLE CYCLE TREATMENT; NERVE CELL DIFFERENTIATION; NEUROENDOCRINE TUMOR; PARANEOPLASTIC SYNDROME; PELVIC PAIN; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PROSTATE BIOPSY; PROSTATE CANCER; SMALL CELL NEUROENDOCRINE CARCINOMA; TUMOR BIOPSY;

EID: 84910068141     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Turbat-Herrera EA, Herrera GA, Gore I, et al. Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study. Arch Pathol Lab Med. 1988; 112: 1100-5.
2. Tanaka M, Suzuki Y, Takaoka K, et al. Progression of prostate cancer to neuroendocrine cell tumor. Int J Urol. 2001; 8: 431-6; discussion 37.
3. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 2004; 64: 9209-16.
4. Tetu B, Ro JY, Ayala AG, et al. Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases. Cancer. 1987; 59: 1803-9.
5. Spiess PE, Pettaway CA, Vakar-Lopez F, et al. Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer. 2007; 110: 1729-37.
6. Christopher ME, Seftel AD, Sorenson K, Resnick MI. Small cell carcinoma of the genitourinary tract: an immunohistochemical, electron microscopic and clinicopathological study. J Urol. 1991; 146: 382-8.
7. Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011; 1: 487-95.
8. Oesterling JE, Hauzeur CG, Farrow GM. Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients. J Urol. 1992; 147: 804-7.
9. Papandreou CN, Daliani DD, Thall PF, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol. 2002; 20: 3072-80.
10. Amato RJ, Logothetis CJ, Hallinan R, et al. Chemotherapy for small cell carcinoma of prostatic origin. J Urol. 1992; 147: 935-7.
11. Palmgren JS, Karavadia SS, Wakefield MR. Unusual and underappreciated: small cell carcinoma of the prostate. Semin Oncol. 2007; 34: 22-9.
12. Sella A, Konichezky M, Flex D, et al. Low PSA metastatic androgen-independent prostate cancer. Eur Urol. 2000; 38: 250-4.
13. Webster GD, Jr, Touchstone JC, Suzuki M. Adrenocortical hyperplasia occurring with metastatic carcinoma of the prostate: report of a case exhibiting increased urinary aldosterone and glucocorticoid excretion. J Clin Endocrinol Metab. 1959; 19: 967-79.
14. Newmark SR, Dluhy RG, Bennett AH. Ectopic adrenocorticotropin syndrome with prostatic carcinoma. Urology. 1973; 2: 666-8.
15. Lovern WJ, Fariss BL, Wettlaufer JN, Hane S. Ectopic ACTH production in disseminated prostatic adenocarcinoma. Urology. 1975; 5: 817-20.
16. Wenk RE, Bhagavan BS, Levy R, et al. Ectopic ACTH, prostatic oat cell carcinoma, and marked hypernatremia. Cancer. 1977; 40: 773-8.
17. Adshead F, De Graeff A, Mansi JL, et al. Small cell carcinoma of the prostate: implications for management. Br J Urol. 1991; 67: 217-8.
18. Nimalasena S, Freeman A, Harland S. Paraneoplastic Cushing's syndrome in prostate cancer: a difficult management problem. BJU Int. 2008; 101: 424-7.
19. Mahadevia PS, Ramaswamy A, Greenwald ES, et al. Hypercalcemia in prostatic carcinoma. Report of eight cases. Arch Intern Med. 1983; 143: 1339-42.
20. Smith DC, Tucker JA, Trump DL. Hypercalcemia and neuroendocrine carcinoma of the prostate: a report of three cases and a review of the literature. J Clin Oncol. 1992; 10: 499-505.
21. Tetu B, Ro JY, Ayala AG, et al. Small cell carcinoma of prostate associated with myasthenic (Eaton-Lambert) syndrome. Urology. 1989; 33: 148-52.
22. Sellwood RA, Spencer J, Azzopardi JG, et al. Inappropriate secretion of antidiuretic hormone by carcinoma of the prostate. Br J Surg. 1969; 56: 933-5.
23. Ghandur-Mnaymneh L, Satterfield S, Block NL. Small cell carcinoma of the prostate gland with inappropriate antidiuretic hormone secretion: morphological, immunohistochemical and clinical expressions. J Urol. 1986; 135: 1263-6.
24. Miyoshi Y, Uemura H, Kitami K, et al. Neuroendocrine differentiated small cell carcinoma presenting as recurrent prostate cancer after androgen deprivation therapy. BJU Int. 2001; 88: 982-3.
25. Okada H, Gotoh A, Ogawa T, et al. Two cases of small cell carcinoma of the prostate. Scand J Urol Nephrol. 1996; 30: 503-8.
26. Hagood PG, Johnson FE, Bedrossian CW, Silverberg AB. Small cell carcinoma of the prostate. Cancer. 1991; 67: 1046-50.
27. Yashi M, Terauchi F, Nukui A, et al. Small-cell neuroendocrine carcinoma as a variant form of prostate cancer recurrence: a case report and short literature review. Urol Oncol. 2006; 24: 313-7.
28. Fjellestad-Paulsen A, Abrahamsson PA, Bjartell A, et al. Carcinoma of the prostate with Cushing's syndrome. A case report with histochemical and chemical demonstration of immunoreactive corticotropin-releasing hormone in plasma and tumoral tissue. Acta Endocrinol (Copenh). 1988; 119: 506-16.
29. Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol. 2008; 32: 65-71.
30. Tan HL, Sood A, Rahimi HA, et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res. 2014; 20: 890-903.
31. Chen H, Sun Y, Wu C, et al. Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. Endocr Relat Cancer. 2012; 19: 321-31.
32. Pinthus JH, Waks T, Schindler DG, et al. WISH-PC2: a unique xenograft model of human prostatic small cell carcinoma. Cancer Res. 2000; 60: 6563-7.
33. Hansel DE, Nakayama M, Luo J, et al. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate. 2009; 69: 603-9.
34. Aparicio A, Tzelepi V, Araujo JC, et al. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate. 2011; 71: 846-56.
35. Lin D, Wyatt AW, Xue H, et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res. 2014; 74: 1272-83.
36. Tzelepi V, Zhang J, Lu JF, et al. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res. 2012; 18: 666-77.
37. Mosquera JM, Beltran H, Park K, et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia. 2013; 15: 1-10.
38. Moore SR, Reinberg Y, Zhang G. Small cell carcinoma of prostate: effectiveness of hormonal versus chemotherapy. Urology. 1992; 39: 411-6.
39. van Haaften-Day C, Raghavan D, Russell P, et al. Xenografted small cell undifferentiated cancer of prostate: possible common origin with prostatic adenocarcinoma. Prostate. 1987; 11: 271-9.
40. Helpap B, Köllermann J. Undifferentiated carcinoma of the prostate with small cell features: immunohistochemical subtyping and reflections on histogenesis. Virchows Arch. 1999; 434: 385-91.
41. Yao JL, Madeb R, Bourne P, et al. Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol. 2006; 30: 705-12.
42. Lotan TL, Gupta NS, Wang W, et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol. 2011; 24: 820-8.
43. Scheble VJ, Braun M, Beroukhim R, et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol. 2010; 23: 1061-7.
44. Ro JY, Tetu B, Ayala AG, Ordonez NG. Small cell carcinoma of the prostate. II. Immunohistochemical and electron microscopic studies of 18 cases. Cancer. 1987; 59: 977-82.
45. Vuitch MF, Mendelsohn G. Relationship of ectopic ACTH production to tumor differentiation: a morphologic and immunohistochemical study of prostatic carcinoma with Cushing's syndrome. Cancer. 1981; 47: 296-9.
46. Schron DS, Gipson T, Mendelsohn G. The histogenesis of small cell carcinoma of the prostate. An immunohistochemical study. Cancer. 1984; 53: 2478-80.
47. di Sant'Agnese PA. Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. Ann Oncol. 2001; 12(suppl 2): S135-S140.
48. Terry S, Beltran H. The many faces of neuroendocrine differentiation in prostate cancer progression. Frontier Oncol. 2014; 4: 60.
49. Clegg N, Ferguson C, True LD, et al. Molecular characterization of prostatic small-cell neuroendocrine carcinoma. Prostate. 2003; 55: 55-64.
50. Tzelepi V, Maitv S, Zhang J, et al. Differential expression of UBE2C and ASCL1 in neuroendocrine carcinoma and adenocarcinoma of the prostate in xenograft models and human samples. USCAP Annual Meeting; 2011; San Antonio, TX.
51. Majumder S. REST in good times and bad: roles in tumor suppressor and oncogenic activities. Cell Cycle. 2006; 5: 1929-35.
52. Lapuk AV, Wu C, Wyatt AW, et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol. 2012; 227: 286-97.
53. Svensson C, Ceder J, Iglesias-Gato D, et al. REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer. Nucleic Acids Res. 2014; 42: 999-1015.
54. Epstein JI, Amin MB, Beltran H, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014; 38: 756-67.
55. Aparicio AM, Harzstark A, Corn PG, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013; 19: 3621-30.
56. Aparicio A, Maitv SI, Wang XI, et al. A molecular characterization of the anaplastic prostate carcinomas. American Association for Cancer Research Annual Meeting; April 2013; Washington, DC. Abstr 7587.
57. Slovin SF. Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior. Nat Clin Pract Oncol. 2007; 4: 551-4.
58. Ciszewski A, Shackleton D, Beer TM. Long-term remission of metastatic small cell carcinoma of the prostate. Urology. 2008; 71: 546. e3-4.
59. Asmis TR, Reaume MN, Dahrouge S, Malone S. Genitourinary small cell carcinoma: a retrospective review of treatment and survival patterns at The Ottawa Hospital Regional Cancer Center. BJU Int. 2006; 97: 711-5.
60. Stein ME, Bernstein Z, Abacioglu U, et al. Small cell (neuroendocrine) carcinoma of the prostate: etiology, diagnosis, prognosis, and therapeutic implications--a retrospective study of 30 patients from the rare cancer network. Am J Med Sci. 2008; 336: 478-88.
61. Hindson DA, Knight LL, Ocker JM. Small-cell carcinoma of prostate. Transient complete remission with chemotherapy. Urology. 1985; 26: 182-4.
62. Socinski MA, Smit EF, Lorigan P, et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol. 2009; 27: 4787-92.
63. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999; 17: 658-67.
64. Rubenstein JH, Katin MJ, Mangano MM, et al. Small cell anaplastic carcinoma of the prostate: seven new cases, review of the literature, and discussion of a therapeutic strategy. Am J Clin Oncol. 1997; 20: 376-80.
65. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA. 1995; 92: 3439-43.
66. Masumori N, Thomas TZ, Chaurand P, et al. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res. 2001; 61: 2239-49.
67. Zhou Z, Flesken-Nikitin A, Corney DC, et al. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res. 2006; 66: 7889-98.